The combination of PN and PI3K inhibitor wortmannin or the mTOR inhibitor, rapamycin (sirolimus) and rapamycin analog, temsirolimus exhibited synergistic toxicity against AML stem cells. Here, MTOR is linked to acute myeloid leukemia.